NICE Bipolar disorder in adolescents – aripiprazole TA292

 In Clinical Guidelines, NICE guidelines

Aripiprazole (Abilify) is a licensed treatment for moderate to severe manic episodes in young people aged 13+ with bipolar 1 disorder.

Other antipsychotics,  such as quetiapine and risperidone, have a similar effectiveness, but have different side-effect profiles.

NICE recommends aripiprazole as a treatment option, so the NHS must make sure it is available for use in line with NICE’s recommendations.

https://www.nice.org.uk/guidance/ta292

 

By en:User:Sponge [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons

Recent Posts

Start typing and press Enter to search

support during medical inspectionsNeuropathic pain